ライフサイエンスコーパス: at baseline and at

1 At baseline and at 3, 6, 12, 18, and 24 months, participants

2 At baseline and at follow-up visit, patients underwent standa

3 al Eye Institute Visual Function Questionnaire (NEI VFQ-25) at baseline and at the end of follow-up.

4 Structural MRI scans were acquired at baseline and at 1-2 follow-up time points (at 12-month int

5 panretinal photocoagulation (PRP), as well as visual acuity at baseline and at 1 year.

6 Demographics and clinical findings were analyzed at baseline and at available follow-ups.

7 FV was applied at baseline and at 6-mo intervals for 3 y.

8 Health status was assessed at baseline and at 1, 6, 12, 36, and 60 months by using the S

9 Disease-specific health status was assessed at baseline and at 30 days and 1 year after TAVR using the Ka

10 Fifty-five children (2 to 7 years of age) were assessed at baseline and at 12 months and grouped as caries free (CF),

11 Youths were assessed at baseline and at four 6-month intervals with regard to gun

12 esponses during an N-back working memory task were assessed at baseline and at the end of treatment.

13 ical, functional, and inflammatory parameters were assessed at baseline and at yearly visits.

14 a representative marker for thymic function, was available at baseline and at 12, 24, and 48 weeks post antiretroviral t

15 heir body weights measured and body mass indices calculated at baseline and at year 3.

16 Memory tests and fMRI scans were conducted at baseline and at the end of the study.

17 ators enrolled in 1993-1997 who provided questionnaire data at baseline and at least once during follow-up (over a median

18 ncluded in the study, with 72 data having GIS(c) score data at baseline and at 6 weeks, and 34 also at 3 weeks.

19 volume (RV), and total lung capacity (TLC) were determined at baseline and at 6 months.

20 tinal endoscopy with duodenal biopsy of the distal duodenum at baseline and at weeks 12 and 24.

21 We performed clinical examinations at baseline and at 2 years, 6 years, and 12 years to ascertai

22 erence tomography (ASOCT) images were obtained in both eyes at baseline and at 6 weeks after LPI.

23 sex, we assessed FMD response to glyceryl trinitrate (GTN) at baseline and at 8 hours and 32 hours after typhoid vaccine

24 drug tests and behavioural interviews to assess individuals at baseline and at 1, 3, 6, 9, and 12 months post-release.

25 779 patients provided data for the primary outcome measure at baseline and at least 1 follow-up.

26 Core temperature and vital signs were measured at baseline and at 5-15-minute intervals for 4 hours after in

27 trength and body mass index (BMI; in kg/m(2)) were measured at baseline and at a 4-y follow-up.

28 Patient-reported outcomes were measured at baseline and at every restaging visit by using the MD Ande

29 Exposure and outcome variables were measured at baseline and at follow-up 7 mo later.Sedentary time was no

30 -hydroxy VD, TGF-beta1, TIMP-1, MMP2 and MMP9 were measured at baseline and at the end of the 6-week study period.

31 y (measured with PET imaging of cerebral glucose metabolism at baseline and at 6 and 12 months after surgery).

32 on and the Kaplan-Meier method to assess variables obtained at baseline and at first follow-up RHC.

33 panded Prostate Index Composite (EPIC) scores were obtained at baseline and at 1, 3, 6, 12, 18, and 24 months and were pl

34 Areas under the curve of 0.76 and 0.69 were obtained at baseline and at follow-up, respectively, with the optimize

35 Plasma samples were obtained at baseline and at the end of each 4-wk period in the fasting

36 angiography and optical coherence tomography were performed at baseline and at 30 and 90 days.

37 ce (CMR)-based tissue characterization was done in all pigs at baseline and at 120 minutes, day 1, day 4, and day 7 after

38 ye Institute were evaluated to determine if nGA was present at baseline and at follow-up using high-density Spectralis OC

39 tor's choice group) completed any of the PRO questionnaires at baseline and at least one other assessment.

40 All subjects received intravitreal ranibizumab at baseline and at week 4, and retreatment injections at subs

41 The ultrasonographic tumor height was recorded at baseline and at 3, 6, 9, and 12 months and at the most rec

42 The BCVA and central macular thickness were recorded at baseline and at 1, 2, and 4 months after treatment with DE

43 ography (SDOCT) images of the optic disc and macula regions at baseline and at 3 and 6 months.

44 A nested case-control analysis of paired plasma samples at baseline and at 3 months was performed in 249 participants

45 Of the 3876 IRIS participants, 3398 had a 3MS score at baseline and at least once during follow-up and were inclu

46 measured by liquid chromatography-tandem mass spectrometry at baseline and at weeks 6 and 12 of the study.Postinterventi

47 ate recurrent viremia, 11 had the same HCV genotype/subtype at baseline and at recurrence.

48 Social support at baseline and at one year was predicted by homelessness (t=

49 A venous blood sample was taken at baseline and at 6 and 12 mo.

50 rvention trial compared the intervention with care as usual at baseline and at 12-month follow-up.